NEW YORK (GenomeWeb News) — Pharsight has licensed its public-source type II diabetes meta-database to an undisclosed biotechnology company, the informatics shop said today.
The deal is the firs time Pharsight has licensed one of its 20 meta-databases, which compare the “simulated” efficacy and safety of candidate drugs against those of existing drugs, the company said.
According to Pharsight, the drug maker plans to use the database to build quantitative models of the “competitive landscape” for oral diabetes treatments that will “help inform clinical program decision-making” for compounds.
In a statement, Pharsight said its diabetes meta-database comprises clinical efficacy and safety measures from 106 clinical trials, including multiple drug classes and comparative treatments, and more than 30 clinical endpoints.
Financial details of the deal were not disclosed.